EMT and EGFR in CTCs cytokeratin negative non-metastatic breast cancer.

Background: AURA study reported 61% objective response rate and progression-free survival of 9.6 months with osimertinib in patients with EGFR/T790M+ non-small cell lung cancer.. Due

To analyze the effects of PA2.26 expression on the phenotype of human epithelial cells, we transiently transfected HeLa carcinoma cells and HaCaT immortalized keratinocytes with

We wondered whether this weak upregulation of SNAIL1 in MDCK-NBL cells was due to the high PRRX1 levels which in turn could activate the expression of miR-15

In this review, we have highlighted the ER stressors that activate the UPR and subsequently EMT, suggesting that the UPR may be an additional upstream signal for the induction of

In parallel, the oncologic management of advanced disease has been revolutionized by the advent of liquid biopsy, i.e., the analysis of tumoral material shed from primary tumors

Pembrolizu- mab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): results from the targeted agent and profiling utiliza- tion

Here we study the role of SFKs catalytic activity in triple-negative/basal-like and metastatic human breast cancer MDA-MB-231 cells employing three well-established

In conclusion, we have shown that (i) YB-1 overexpression promotes EMT features, cell migration, and invasion in breast cancer cell lines; (ii) YB-1 knockdown partially reverts